Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.4 (CiteScore Tracker 3.4)
Index Copernicus  – 161.11; MEiN – 140 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2019, vol. 28, nr 8, August, p. 1043–1050

doi: 10.17219/acem/94392

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Identification of alternative splicing and lncRNA genes in pathogenesis of small cell lung cancer based on their RNA sequencing

Youming Lei1,A,D, Yunfei Shi1,A,B, Jin Duan1,B,C, Yinqiang Liu1,C,E, Guoli Lv1,C,E, Rou Shi1,B,E, Fujun Zhang1,B,E, Qingmei Yang1,B,C, Wei Zhao1,A,F

1 The First Affiliated Hospital of Kunming Medical University, China


Background. The molecular mechanisms involved in small-cell lung cancer (SCLC) are largely unknown. Recent studies have suggested that long non-coding RNAs (lncRNAs) are likely to play a critical role.
Objectives. There is an urgent need for suitable molecular biomarkers for SCLC diagnosis and for assessing patient prognosis.
Material and Methods. In this study, we used public databases to identify mRNA-like candidate lncRNAs. A multi-step computational approach was used to construct a functional SCLC lncRNAs-mediated competing with endogenous RNA (ceRNA) network (LMCN) by integrating genome-wide lncRNAs and mRNA expression profiles, miRNA-target interactions, functional analyses, and clinical survival analyses.
Results. The results revealed the significance of lncRNAs interactions with ceRNAs in SCLC, indicating that integration of expression profiles and alternative splicing could be used to identify biomarkers and the underlying pathological changes. The following genes: EPB41L4A-AS1, HOXA-AS2, XIST, DLEU2, FGD5-AS1, ALMS1-IT1, SNHG12, MIR17HG, MIR4720, and SCARNA10 in cluster, as well as shared alternative splicing events, were considered to be critical genes.
Conclusion. Olfactory transduction and endocytosis were the top-enriched pathways in SCLC. The selected cluster, including critical genes, might also be a potential pathway of SCLC pathogenesis. As a result, this research provides the perspective information to explore the potential critical genes and its pathways in SCLC therapy.

Key words

alternative splicing, small-cell lung cancer (SCLC), critical genes

References (25)

  1. Taromi S, Catusse J, Elverfeldt DV, et al. PO-33-Heparin suppresses progression of small cell lung cancer (SCLC) in an orthotopic mouse model. Thromb Res. 2016;140(Suppl 1):S188.
  2. Liu Y, Liu YS, Wu PF, et al. Brain microvascular endothelium induced-annexin A1 secretion contributes to small cell lung cancer brain meta­stasis. Int J Biochem Cell Biol. 2015;66:11–19.
  3. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98–110.
  4. Guttman M, Donaghey J, Carey BW, et al. lincRNAs act in the circuitry controlling pluripotency and differentiation. Nature. 2011;477(7364):295–300.
  5. Guo Q, Cheng Y, Liang T, et al. Comprehensive analysis of lncRNA-mRNA co-expression patterns identifies immune-associated lncRNA biomarkers in ovarian cancer malignant progression. Sci Rep. 2015;5:17683.
  6. Ebert MS, Sharp PA. Emerging roles for natural microRNA sponges. Curr Biol. 2010;20(19):R858–R861.
  7. Wang P, Ning S, Zhang Y, et al. Identification of lncRNA-associated competing triplets reveals global patterns and prognostic markers for cancer. Nucleic Acids Res. 2015;43(7):3478–3489.
  8. Wang J, Liu X, Wu H, et al. CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer. Nucleic Acids Res. 2010;38(16):5366–5383.
  9. Sumazin P, Yang X, Chiu HS, et al. An extensive microRNA-mediated network of RNA-RNA interactions regulates established oncogenic pathways in glioblastoma. Cell. 2011;147(2):370–381.
  10. Pradella D, Naro C, Sette C, Ghigna C. EMT and stemness: Flexible processes tuned by alternative splicing in development and cancer progression. Mol Cancer. 2017;16(1):8.
  11. Li Y, Sun N, Lu Z, et al. Prognostic alternative mRNA splicing signature in non-small cell lung cancer. Cancer Lett. 2017;393:40–51.
  12. Huertas CS, Dominguez-Zotes S, Lechuga LM. Analysis of alternative splicing events for cancer diagnosis using a multiplexing nanophotonic biosensor. Sci Rep. 2017;7:41368.
  13. Mei H, Wang Y, Fan J, Lin Z. Alternative splicing of S6K1 promotes non-small cell lung cancer survival. Tumour Biol. 2016;37(10):13369–13376.
  14. Ghosh S, Chan CK. Analysis of RNA-seq data using TopHat and Cufflinks. Methods Mol Biol. 2016;1374:339–361.
  15. Trapnell C, Roberts A, Goff L, et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc. 2012;7(3):562–578.
  16. Ritchie ME, Phipson B, Wu D, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.
  17. Rainero E. Extracellular matrix endocytosis in controlling matrix turnover and beyond: Emerging roles in cancer. Biochem Soc Trans. 2016;44(5):1347–1354.
  18. Vassie JA, Whitelock JM, Lord MS. Endocytosis of cerium oxide nano­particles and modulation of reactive oxygen species in human ovarian and colon cancer cells. Acta Biomater. 2017;50:127–141.
  19. Yu XW, Lin S, Du HZ, et al. Synergistic combination of DT-13 and topotecan inhibits human gastric cancer via myosin IIA-induced endocytosis of EGF receptor in vitro and in vivo. Oncotarget. 2016;7(22):32990–33003.
  20. Kim JH, Wang A, Conti MA, Adelstein RS. Nonmuscle myosin II is required for internalization of the epidermal growth factor receptor and modulation of downstream signaling. J Biol Chem. 2012;287(33):27345–27358.
  21. Yu X, Li Z, Zheng H, Chan MT, Wu WK. NEAT1: A novel cancer-related long non-coding RNA. Cell Prolif. 2017;50(2). doi:10.1111/cpr.12329
  22. Barry G, Briggs JA, Hwang DW, et al. The long non-coding RNA NEAT1 is responsive to neuronal activity and is associated with hyperexcitability states. Sci Rep. 2017;7:40127.
  23. Jiang L, Huang J, Higgs BW, et al. Genomic landscape survey identifies SRSF1 as a key oncodriver in small cell lung cancer. PLoS Genet. 2016;12(4):e1005895.
  24. Feng J, Zhang X, Zhu H, Wang X, Ni S, Huang J. High expression of FoxP1 is associated with improved survival in patients with non-small cell lung cancer. Am J Clin Pathol. 2012;138(2):230–235.
  25. Santos ME, Athanasiadis A, Leitao AB, DuPasquier L, Sucena E. Alternative splicing and gene duplication in the evolution of the FoxP gene subfamily. Mol Biol Evol. 2011;28(1):237–247.